1h Free Analyst Time
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2018Speak directly to the analyst to clarify any post sales queries you may have.
Summary:
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 5 - Pipeline Review, H2 2018, outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 11 and 2 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively. Report covers products from therapy areas Central Nervous System and Genetic Disorders which include indications Anxiety Disorders, Depression, Schizophrenia, Autism, Cognitive Impairment Associated With Schizophrenia (CIAS), Drug-Induced Dyskinesia, Dyskinesia, Fragile X Syndrome, Major Depressive Disorder, Pervasive Developmental Disorder (PDD), Alcohol Addiction, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Cognitive Impairment, Dementia, Mania, Neurology, Opium (Opioid) Addiction, Pain, Parkinson's Disease, Rett Syndrome and Spasmodic Torticollis (Cervical Dystonia).
Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope:
- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
- The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics
Reasons to buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Aevi Genomic Medicine Inc
Bristol-Myers Squibb Co
Eisai Co Ltd
Eli Lilly and Co
Heptares Therapeutics Ltd
Johnson & Johnson
Merz Pharma GmbH & Co KgaA
Novartis AG
Richter Gedeon Nyrt
Sumitomo Dainippon Pharma Co Ltd
Toray Industries Inc
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles
AEVI-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alloswitch-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbaclofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-952048 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-955829 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipraglurant ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipraglurant IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSR-98776 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasoracetam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GET-73 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-14242 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-46778212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSN-2814617 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mavoglurant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAM-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize mGlu5 for Rett Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize mGluR5 for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize MGLUR5 for Anxiety Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0092273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0431316 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones
Featured News & Press Releases
Jul 19, 2018: Aevi Genomic Medicine Announces Novel Co-crystal Version of AEVI-
Jun 12, 2018: Aevi Genomic Medicine Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD
May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-
Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-
Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder
Oct 17, 2016: Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia
Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD
Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society
Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Addex Therapeutics Ltd, H2 2018
Pipeline by Aevi Genomic Medicine Inc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Eisai Co Ltd, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Heptares Therapeutics Ltd, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Merz Pharma GmbH & Co KgaA, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Richter Gedeon Nyrt, H2 2018
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018
Pipeline by Toray Industries Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Discontinued Products, H2 2018
Discontinued Products, H2 2018 (Contd..1), H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Addex Therapeutics Ltd
- Aevi Genomic Medicine Inc
- Bristol-Myers Squibb Co
- Eisai Co Ltd
- Eli Lilly and Co
- Heptares Therapeutics Ltd
- Johnson & Johnson
- Merz Pharma GmbH & Co KgaA
- Novartis AG
- Richter Gedeon Nyrt
- Sumitomo Dainippon Pharma Co Ltd
- Toray Industries Inc
